NCT01886469
A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jul 31, 2013
Completion: Sep 30, 2013